- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 23, Pages 2159-2170
Publisher
Massachusetts Medical Society
Online
2023-03-28
DOI
10.1056/nejmoa2302312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- (2022) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype
- (2022) Megan A. Clarke et al. JAMA Oncology
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
- (2020) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
- (2019) Megan A. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
- (2019) Yoland Catherine Antill et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
- (2019) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
- (2017) Zibing Wang et al. OncoImmunology
- Endometrial cancer: Not your grandmother's cancer
- (2016) Jessica N. McAlpine et al. CANCER
- Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions
- (2016) Y. Louise Wan et al. GYNECOLOGIC ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Multiple Testing in Group Sequential Trials Using Graphical Approaches
- (2013) Willi Maurer et al. Statistics in Biopharmaceutical Research
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells
- (2013) Mario Roselli et al. OncoImmunology
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
- (2011) W. Joost Lesterhuis et al. JOURNAL OF CLINICAL INVESTIGATION
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started